Cerebras has completed its IPO. The useful question for investors is now how the listed business turns its AI infrastructure commitments into revenue and cash flow, rather than when its shares will become available.
Update, September 20, 2026: This guide replaces preliminary roadshow terms and removes an outdated May stock-price snapshot. The offering dates and price below are historical facts; market prices belong on the TECHi CBRS quote page.
Final Cerebras IPO terms
Cerebras began trading on the Nasdaq Global Select Market under CBRS on May 14, 2026. Its May 15 closing announcement confirms a $185 offering price and 34.5 million shares sold, including the full 4.5 million-share underwriter option. Gross proceeds were approximately $6.38 billion, before underwriting discounts, commissions and offering expenses.
That supersedes the preliminary pricing ranges previously displayed on this page. The final SEC prospectus is the appropriate reference for the completed offering; a roadshow document describes a proposed transaction and should not be used as the final deal record.
IPO proceeds are not Cerebras’ valuation
The money raised in an offering and the value of a company are different figures. Gross proceeds multiply the shares sold in the transaction by their offer price. Market capitalization uses the relevant outstanding share count and market price. A fully diluted valuation may include additional securities and assumptions.
Confusing those measures can produce a dramatically wrong valuation comparison. Dividing the IPO proceeds by annual revenue does not produce a price-to-sales multiple for the whole company. Nor should an old valuation headline be carried forward when the share price or share-count basis has changed.
For an up-to-date comparison, start with the market capitalization and timestamp on CBRS, then examine the reporting period on its financial statements. Compare like periods and distinguish basic shares, diluted shares and securities that could create future dilution. The IPO price is a useful historical reference, not a valuation floor.
The post-IPO financial record
Cerebras’ August 12 results for the quarter ended June 30, 2026 reported $180.1 million in GAAP revenue and a $450.5 million GAAP net loss. The release separately reported $209.9 million in non-GAAP core revenue. Those are distinct measures and should not be combined into a single growth or profitability claim.
The same release said Cerebras expected its AWS disaggregated inference offering to reach Amazon Bedrock in the first quarter of 2027. That was a forward-looking company expectation as of August 12, not confirmation that deployment had already happened.
TECHi’s practical comparison is to place reported earnings beside the financials and share-price history. Revenue growth can coexist with large losses. A headline about customer demand does not by itself tell a shareholder how much cash the business needs to deliver that demand. Read the adjustments behind core measures before comparing them with GAAP figures or another company’s results.
Why OpenAI and AWS mattered to the IPO story
OpenAI’s January 14 partnership announcement described plans to add 750 MW of Cerebras compute in phases through 2028. Its emphasis was low-latency inference: reducing the delay between an AI request and the response. This was a capacity plan, not a statement that every tranche was already operating or generating revenue.
AWS’s March 13 announcement described combining Trainium for prompt processing with Cerebras CS-3 systems for output generation. The announced architecture separated two parts of inference that have different computing demands. Readers should use subsequent issuer updates, including the dated August expectation above, when assessing delivery timing.
For investors, the distinction between an announcement and delivered capacity matters. A partner relationship can support demand while still requiring manufacturing, data-center spending and successful integration. Treat contract value, capacity plans, recognized revenue and cash receipts as separate stages. None is an automatic substitute for the others.
Buying CBRS after the IPO
The original IPO allocation is over. Investors considering CBRS now are considering a listed security through a broker, with execution at the available market price rather than a guaranteed historical offer price. Broker availability, order types, costs and eligibility vary.
An order entered outside normal trading hours may not execute at the last displayed price. Check whether a quote is real-time, delayed or from the previous session. The removed May snapshot did not answer that question for a September reader; keeping a static price in this guide would recreate the same problem.
Use the CBRS news feed to find subsequent company reporting, and the peer comparison to examine differences in business mix. A specialized infrastructure company and a diversified semiconductor supplier can have very different customer concentration, margins and financing needs even when both are described as AI stocks.
Risks to assess after listing
The issuer’s August results release identifies dependence on significant customers, capacity and financing requirements, execution of commercial relationships and competition among its risks. These remain more useful questions than whether an old roadshow range looked inexpensive.
A sound review separates business progress from the price paid for it. Check whether reported growth is turning into durable margins, how much capital is needed for expansion, and whether additional securities dilute existing holders. Use the latest filing for each measure and keep its reporting date attached. Forecasts and partner plans should remain labeled as expectations until there is evidence of delivery.
The completed offering settles the IPO timetable. It does not settle the investment case. This page preserves the deal record and directs ongoing price, earnings and valuation analysis to dated sources so that historical terms do not masquerade as current market information.
Investment disclaimer: This article is for informational and educational purposes only and is not personalized investment advice or a recommendation to buy or sell a security.
Comments